Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 7/20 | 0.47 |
| ▸ | DCUN1D1 | Q96GG9 | 7/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | CCR5 | P51681 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30227256 | 1.00 | UBE2M (0.47) | UBE2MDCUN1D1MCHR1LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL1449356 | 0.99 | UBE2M (0.46) | UBE2MDCUN1D1MCHR1LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL1450247 | 0.93 | UBE2M (0.48) | UBE2MDCUN1D1MCHR1LMNAALDH1A1 | |
| SCHEMBL2252476 | 0.92 | UBE2M (0.43) | UBE2MDCUN1D1MCHR1LMNAALDH1A1 | |
| SCHEMBL1448587 | 0.91 | CCR5 (0.41) | UBE2MDCUN1D1MCHR1LMNAALDH1A1 | |
| SCHEMBL30227264 | 0.91 | CCR5 (0.41) | UBE2MDCUN1D1MCHR1LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL1448924 | 0.91 | UBE2M (0.49) | UBE2MDCUN1D1MCHR1LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL1449812 | 0.91 | CCR5 (0.42) | UBE2MDCUN1D1MCHR1LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL1448877 | 0.90 | UBE2M (0.48) | UBE2MDCUN1D1MCHR1LMNAALDH1A1 | |
| SCHEMBL1982347 | 0.88 | ALDH1A1 (0.49) | UBE2MDCUN1D1LMNAALDH1A1PTBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385040-A1 | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | ONO Pharmaceutical Co., Ltd. (JP) | 2011-11-09 | — | — | EP | claimed |
| US-20060178399-A1 | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-10 | — | — | US | claimed |
| EP-1604981-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-14 | — | — | EP | claimed |
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222069-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | INCELLDX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| EP-2385040-A1 | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | ONO Pharmaceutical Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-7910741-B2 | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20070270429-A1 | Function Inhibitor of Effector Cell | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20060178399-A1 | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1623721-A1 | EFFECTOR CELL FUNCTION INHIBITOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-02-08 | — | — | EP | disclosed |
| EP-1604981-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178399-A1 | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient | HLA-DRB1, ELANE, MMP8 | UBE2M 3256/4885DCUN1D1 3114/4885MCHR1 4444/4885 |
| US-20070270429-A1 | Function Inhibitor of Effector Cell | CCR5, CXCR3, CCR1 | UBE2M 4433/4885DCUN1D1 2863/4885MCHR1 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.